Peter Hempshall, CEO of Deallus, is partnering with Rita Numerof, Founder & President of Numerof & Associates, for a discussion series centered on the lasting impact that COVID-19 will have on business models in the healthcare industry. Tune in to be part of a discussion on how the pandemic has accelerated key market shifts, how organizations will need to operate differently, and what solutions can be offered for successfully moving businesses forward in this new reality.
As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.
As COVID-19 continues to disrupt normalcy across the globe, China is responding with innovation in online health delivery and telemedicine. How has China encouraged telemedicine uptake? What are the factors contributing to China’s relatively quick utilization of telemedicine in the face of COVID-19? And what learnings can we gain from taking a closer look? We explore these questions in our latest addition to our COVID-19+Pharma Series.
COVID-19 is throwing a wrench in years’ worth of launch planning, introducing complications and delays into the regulatory process and severely constricting promotional and educational opportunities for new products. How is the pharmaceutical industry responding to these changes in well-laid plans? How are regulatory bodies responding? We consider the potential impact of the pandemic on launch timing and strategy here.
As the impact of COVID-19 pandemic continues to expand globally, pharmaceutical and biotech players are beginning to feel the disruptive effects of the outbreak. New clinical trials will be significantly delayed as companies continue to face challenges arising from COVID-19, from potential patient quarantines, to site closures, travel limitations or interruptions to the supply chain for new investigational products.